BFSG LLC’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.81M | Sell |
49,179
-111
| -0.2% | -$5.26K | 0.17% | 134 |
|
|
2025
Q4 | $2.51M | Sell |
49,290
-74,674
| -60% | -$3.82M | 0.24% | 117 |
|
|
2025
Q3 | $6.88M | Buy |
123,964
+6,514
| +6% | +$381K | 0.67% | 42 |
|
|
2025
Q2 | $8.11M | Buy |
117,450
+1,943
| +2% | +$132K | 0.91% | 26 |
|
|
2025
Q1 | $8.02M | Buy |
115,507
+12,515
| +12% | +$1.03M | 0.98% | 24 |
|
|
2024
Q4 | $8.86M | Buy |
102,992
+16,375
| +19% | +$1.77M | 1.04% | 22 |
|
|
2024
Q3 | $10.3M | Buy |
86,617
+42,662
| +97% | +$5.69M | 1.2% | 15 |
|
|
2024
Q2 | $6.27M | Sell |
43,955
-2,590
| -6% | -$343K | 0.8% | 33 |
|
|
2024
Q1 | $5.98M | Sell |
46,545
-209
| -0.4% | -$24.9K | 0.79% | 36 |
|
|
2023
Q4 | $4.84M | Buy |
46,754
+36
| +0.1% | +$3.56K | 0.7% | 44 |
|
|
2023
Q3 | $4.25M | Buy |
46,718
+3,278
| +8% | +$289K | 0.69% | 51 |
|
|
2023
Q2 | $3.52M | Buy |
43,440
+6,564
| +18% | +$536K | 0.6% | 61 |
|
|
2023
Q1 | $2.93M | Sell |
36,876
-60
| -0.2% | -$4.25K | 0.54% | 72 |
|
|
2022
Q4 | $2.5M | Sell |
36,936
-850
| -2% | -$49.8K | 0.5% | 73 |
|
|
2022
Q3 | $1.88M | Sell |
37,786
-860
| -2% | -$46.1K | 0.4% | 86 |
|
|
2022
Q2 | $2.15M | Sell |
38,646
-508
| -1% | -$28.2K | 0.39% | 84 |
|
|
2022
Q1 | $2.17M | Sell |
39,154
-1,788
| -4% | -$91.8K | 0.34% | 84 |
|
|
2021
Q4 | $2.29M | Sell |
40,942
-2,310
| -5% | -$125K | 0.32% | 96 |
|
|
2021
Q3 | $2.08M | Sell |
43,252
-670
| -2% | -$32.4K | 0.32% | 97 |
|
|
2021
Q2 | $1.84M | Sell |
43,922
-2,186
| -5% | -$84.7K | 0.33% | 91 |
|
|
2021
Q1 | $1.55M | Sell |
46,108
-11,188
| -20% | -$398K | 0.25% | 104 |
|
|
2020
Q4 | $2M | Sell |
57,296
-1,130
| -2% | -$39.1K | 0.33% | 88 |
|
|
2020
Q3 | $2.03M | Sell |
58,426
-1,674
| -3% | -$55.8K | 0.38% | 77 |
|
|
2020
Q2 | $1.97M | Sell |
60,100
-200
| -0.3% | -$6.38K | 0.42% | 71 |
|
|
2020
Q1 | $1.81M | Sell |
60,300
-752
| -1% | -$22.4K | 0.47% | 70 |
|
|
2019
Q4 | $1.77M | Sell |
61,052
-1,200
| -2% | -$33.2K | 0.33% | 87 |
|
|
2019
Q3 | $1.61M | Sell |
62,252
-5,860
| -9% | -$148K | 0.36% | 82 |
|
|
2019
Q2 | $1.74M | Sell |
68,112
-5,510
| -7% | -$136K | 0.68% | 46 |
|
|
2019
Q1 | $1.93M | Sell |
73,622
-2,730
| -4% | -$67.1K | 0.72% | 48 |
|
|
2018
Q4 | $1.76M | Sell |
76,352
-4,330
| -5% | -$96.2K | 0.8% | 45 |
|
|
2018
Q3 | $1.9M | Sell |
80,682
-1,302
| -2% | -$31.8K | 0.8% | 48 |
|
|
2018
Q2 | $1.89M | Sell |
81,984
-90
| -0.1% | -$2.14K | 0.83% | 45 |
|
|
2018
Q1 | $2.02M | Buy |
82,074
+510
| +0.6% | +$13.4K | 0.9% | 41 |
|
|
2017
Q4 | $2.19M | Sell |
81,564
-2,160
| -3% | -$54.9K | 0.92% | 36 |
|
|
2017
Q3 | $2.02M | Sell |
83,724
-1,190
| -1% | -$26.9K | 0.91% | 43 |
|
|
2017
Q2 | $1.82M | Sell |
84,914
-2,614
| -3% | -$52.7K | 0.9% | 45 |
|
|
2017
Q1 | $1.5M | Buy |
+87,528
| New | +$1.52M | 0.75% | 58 |
|
Other funds holding NVO
DAM
F
BFSG LLC's NVO Position: Q1 2026 in Review
BFSG LLC reduced its Novo Nordisk (NVO) stake by 0.23% in Q1 2026, selling an estimated $5.26K and leaving 49,179 shares worth $1.81M. The position accounts for 0.17% of the portfolio, ranked #134.
BFSG LLC first reported a position in NVO in Q1 2017 and has held it in 37 quarters since. The position peaked at $10.3M in Q3 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- BFSG LLC held 49,179 shares of Novo Nordisk worth $1.81M as of Q1 2026.
- BFSG LLC sold 111 Novo Nordisk shares in Q1 2026, an estimated $5.26K.
- Novo Nordisk made up 0.17% of BFSG LLC's portfolio in Q1 2026, its #134 holding.
- BFSG LLC first reported a position in Novo Nordisk in Q1 2017 and has held it in 37 quarters since.
- BFSG LLC's Novo Nordisk position peaked at $10.3M in Q3 2024.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on BFSG LLC's 13F filing for Q1 2026, filed 29 Apr 2026.